scholarly journals Persistent bone marrow depression following short-term treatment with temozolomide

2016 ◽  
pp. bcr2016215797 ◽  
Author(s):  
Kathrine Vandraas ◽  
Geir Erland Tjønnfjord ◽  
Tom Børge Johannesen ◽  
Petter Brandal
Keyword(s):  
Bone Marrow ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Bone Marrow Depression

scholarly journals Short-Term Treatment with Novel Ribonucleotide Reductase Inhibitors Trimidox and Didox Reverses Late-Stage Murine Retrovirus-Induced Lymphoproliferative Disease with Less Bone Marrow Toxicity Than Hydroxyurea

2002 ◽  
Vol 13 (5) ◽  
pp. 305-314 ◽  
Author(s):  
CN Mayhew ◽  
JD Phillips ◽  
ML Cibull ◽  
HL Elford ◽  
VS Gallicchio
Keyword(s):  
Bone Marrow ◽  
Ribonucleotide Reductase ◽  
Late Stage ◽  
White Blood Cells ◽  
Lymphoproliferative Disease ◽  
Term Treatment ◽  
Bone Marrow Toxicity ◽  
Short Term ◽  
Short Term Treatment ◽  
Leukaemia Virus

We evaluated the ability of a short course of treatment with the ribonucleotide reductase (RR) inhibitor hydroxyurea (HU) and two novel RR inhibitors Trimidox (TX) and Didox (DX) to influence late-stage murine retrovirus-induced lymphoproliferative disease. LPBM5 murine leukaemia virus retrovirus-infected mice were treated daily with HU, TX or DX for 4 weeks, beginning 9 weeks post-infection, after development of immunodeficiency and lymphoproliferative disease. Drug effects on disease progression were determined by evaluating spleen weight and histology. Effects on haematopoiesis were determined by measuring peripheral blood indices (white blood cells and haematocrit) and assay of femur cellularity and femoral and splenic content of colony-forming units granulocytemacrophage (CFU-GM) and burst-forming units-erythroid (BFU-E). HU, TX and DX partially reversed late-stage retrovirus-induced disease, resulting in spleen weights significantly below pre-treatment values. Spleen histology was also improved by RR inhibitor treatment (DX>TX>HU). However, as expected, HU was significantly myelosuppressive, inducing a reduction in peripheral indices associated with depletion of femoral CFU-GM and BFU-E. In contrast, although TX and DX were moderately myelosuppressive, both drugs were significantly better tolerated than HU. In summary, short-term treatment in late-stage murine retroviral disease with HU, TX or DX induced dramatic reversal of disease pathophysiology. However, the novel RR inhibitors TX and DX had more effective activity and significantly less bone marrow toxicity than HU.

AB0298 LONG-TERM SUPPRESSION OF RAPID RADIOGRAPHIC PROGRESSION AFTER DISCONTINUATION/REDUCTION OF SHORT-TERM BIOLOGIC THERAPY IN PATIENTS WITH EARLY DESTRUCTIVE RHEUMATOID ARTHRITIS ACCOMPANIED WITH EXTENSIVE BONE MARROW EDEMA.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1448-1449
Author(s):  
K. Katayama ◽  
T. Okubo ◽  
T. Sato ◽  
R. Fukai ◽  
M. Yuichi ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Marrow ◽  
Biological Treatment ◽  
Bone Marrow Edema ◽  
Radiographic Progression ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Significant Difference ◽  
Marrow Edema

Background:We reported that short-term (3 or 6 months) treatment with biologics (BIO) group compared with conventional synthetic non-biological disease-modifying anti rheumatic drug (csDMARDs) enhanced group is more effective in the reducing bone marrow edema (BE) and improving structural remission in early destructive RA accompanied with extensive hand BM despite csDMARDs therapy (1).Objectives:Purpose of this extended study is to investigate whether suppression of RRP will maintain after the discontinuation/reduction of short term biological treatment during over 1 year. Clinical registration number; (UMIN-CTR 000013614)(Figure 1)Methods:RA disease activity was evaluated by DAS28-ESR after BIO withdrawal/reduction at 12 months. Bone destruction was determined by modified total Sharp scoring (mTSS) using by conventional radiography expressed as yearly progression of mTSS (ΔmTSS/y) at 12 months. Statistical analysis were performed by t-test or Wilcoxon rank sum test using SAS .13.2 softwareResults:Fourteen out of 23 patients in BIO group achieved improvement of BM (>70% improvement of baseline BE). Three patient continued BIO. Among 11 patient started to discontinuation/reduction of BIO, 7 patients were successful for discontinuation of BIO. Four patients flared (Table 1). Mean DAS28-ESR, mean ΔmTSS/y at 0, 12 months after discontinuation in 7 patients were 1.77, 2.02 and -0.66,-0.44, respectively (no significant difference between values in 0 and12 month). In contrast, those in 4 flared patients were 1.91, 4.08 and 0, 1.83, respectively (significant difference). Finally, to resolve baseline prognostic factors for improvement of BE for biological treatment, we compared baseline data between 14 BE improved and 9 BE unimproved RA patients. Low DAS28-ESR at 3 or 6 month (P<0.001) are indicated for significant prognostic factor for improvement of BE, although Low DAS28-ESR at baseline (P=0.07) may associate improvement of BE.Table 1.Summary of 1 year clinical data in 11 patients treated in BIO discontinuation/reduction after improvement of BE by short-term treatment of BIOConclusion:Results of this study indicated suppression of RRP will maintain during over 1 year after the discontinuation of short term biological treatment in some patients. We recommend that a short-term treatment with biologics for early RA patients, who are resistant to non-bio DMARDs therapy and at high risk to transit to RRP, will be an effective and economical treatment strategy.References:[1]K. Katayama, T. Okubo, S. Sato et al. Prevention of extensive bone marrow edema and consequent rapid radiographic progression by short term usage of biologics in DMARDs resistant patients with early destructive rheumatoid arthritis. EULAR meeting. FRI 0124(2018).Disclosure of Interests:None declared

scholarly journals KIDNEY INJURY MOLECULE-1 AS AN EARLY AMIKACIN-INDUCED NEPHROTOXICITY MARKER IN PATIENTS WITH SEPSIS HOSPITALIZED IN THE INTENSIVE CARE UNIT

2019 ◽  
pp. 277-279
Author(s):  
TRISNI UNTARI DEWI ◽  
INSTIATY . ◽  
RUDIANTO SEDONO ◽  
GESTINA ALISKA ◽  
MUHAMMAD KHIFZHON AZWAR ◽  
...  
Keyword(s):  
Intensive Care ◽  
Kidney Injury ◽  
Term Treatment ◽  
Short Term ◽  
Short Term Treatment ◽  
Safe Level ◽  
Study Results ◽  
Early Biomarker ◽  
Kidney Injury Molecule 1 ◽  
Trough Plasma

Objective: This study sought to determine the correlation between trough plasma amikacin concentrations and urinary normalized kidney injurymolecule-1 (KIM-1) concentrations as an early biomarker of nephrotoxicity in patients with sepsis who are hospitalized in an intensive care unit.Methods: In this pilot study, 12 patients with sepsis were treated with amikacin 1000 mg/day between May 2015 and September 2015. The correlationbetween trough plasma amikacin concentrations measured after the third dose and the elevation of urinary normalized KIM-1 concentrations afterthe third amikacin dose relative to the first/second dose was evaluated.Results: In total, three patients had trough plasma amikacin concentrations exceeding the safe level (>10 μg/ml). Furthermore, eight patientsdisplayed higher normalized KIM-1 concentrations after third dose than after the first/second dose; however, there was no correlation betweentrough amikacin concentrations and the elevation of urinary normalized KIM-1 concentrations (r=0.3, p=0.3).Conclusion: The study results illustrated that short-term treatment with an amikacin dose of 1000 mg/day was generally safe in patients with sepsis.

Instrumentation in Voice Assessment and Treatment

1997 ◽  
Vol 6 (4) ◽  
pp. 9-16 ◽  
Author(s):  
Alison Behrman ◽  
Robert F. Orlikoff
Keyword(s):  
Clinical Practice ◽  
Scientific Method ◽  
Term Treatment ◽  
Treatment Goals ◽  
Short Term ◽  
Short Term Treatment ◽  
Voice Assessment ◽  
Assessment And Treatment ◽  
Computer Based ◽  
The Voice

Sophisticated, computer-based instrumentation has become increasingly available to the voice clinician. Yet substantial questions remain regarding its clinical necessity and usefulness. A theoretical model based on the scientific method is developed as a framework that can be used to guide the clinician in the selection and application of instrumental measures. Using the process of hypothesis testing, instrumentation is presented as an integral component of clinical practice. The uses of instrumental measures, and their relevance to long- and short-term treatment goals, are addressed. Clinical examples are presented to illustrate the incorporation of instrumentation and the scientific method into assessment and treatment.

Sign in / Sign up

Export Citation Format

Share Document